Ontology highlight
ABSTRACT:
SUBMITTER: Dounay AB
PROVIDER: S-EPMC4025856 | biostudies-other | 2012 Mar
REPOSITORIES: biostudies-other
ACS medicinal chemistry letters 20120125 3
Kynurenine aminotransferase (KAT) II has been identified as a potential new target for the treatment of cognitive impairment associated with schizophrenia and other psychiatric disorders. Following a high-throughput screen, cyclic hydroxamic acid PF-04859989 was identified as a potent and selective inhibitor of human and rat KAT II. An X-ray crystal structure and (13)C NMR studies of PF-04859989 bound to KAT II have demonstrated that this compound forms a covalent adduct with the enzyme cofactor ...[more]